Barclays PLC Has $539,000 Stock Holdings in Treace Medical Concepts, Inc. (NASDAQ:TMCI)

Barclays PLC decreased its stake in Treace Medical Concepts, Inc. (NASDAQ:TMCI) by 3.0% in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 77,285 shares of the company’s stock after selling 2,411 shares during the quarter. Barclays PLC owned 0.12% of Treace Medical Concepts worth $539,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. William Blair Investment Management LLC lifted its position in shares of Treace Medical Concepts by 22.9% in the 4th quarter. William Blair Investment Management LLC now owns 2,938,848 shares of the company’s stock valued at $21,865,000 after acquiring an additional 546,787 shares in the last quarter. JPMorgan Chase & Co. boosted its position in shares of Treace Medical Concepts by 56.6% in the fourth quarter. JPMorgan Chase & Co. now owns 1,977,219 shares of the company’s stock worth $14,711,000 after buying an additional 714,984 shares during the period. Geode Capital Management LLC grew its holdings in shares of Treace Medical Concepts by 2.1% during the fourth quarter. Geode Capital Management LLC now owns 1,062,765 shares of the company’s stock valued at $7,909,000 after buying an additional 22,159 shares in the last quarter. Trexquant Investment LP raised its position in Treace Medical Concepts by 7.0% during the fourth quarter. Trexquant Investment LP now owns 318,889 shares of the company’s stock valued at $2,373,000 after buying an additional 21,000 shares during the period. Finally, Bank of New York Mellon Corp lifted its stake in Treace Medical Concepts by 2.6% in the 4th quarter. Bank of New York Mellon Corp now owns 125,945 shares of the company’s stock worth $937,000 after acquiring an additional 3,215 shares in the last quarter. Institutional investors and hedge funds own 84.08% of the company’s stock.

Analyst Ratings Changes

TMCI has been the topic of a number of research reports. Truist Financial dropped their target price on Treace Medical Concepts from $9.50 to $8.00 and set a “hold” rating on the stock in a report on Friday, April 11th. BTIG Research upgraded shares of Treace Medical Concepts from a “neutral” rating to a “buy” rating and set a $16.00 target price for the company in a research report on Tuesday, February 4th. Five analysts have rated the stock with a hold rating and two have given a buy rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus target price of $9.93.

Insiders Place Their Bets

In other news, insider Sean F. Scanlan sold 50,000 shares of the business’s stock in a transaction on Monday, March 17th. The shares were sold at an average price of $7.97, for a total value of $398,500.00. Following the completion of the sale, the insider now directly owns 364,081 shares in the company, valued at approximately $2,901,725.57. The trade was a 12.07 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Company insiders own 27.72% of the company’s stock.

Treace Medical Concepts Price Performance

NASDAQ TMCI opened at $7.52 on Friday. The company has a quick ratio of 2.98, a current ratio of 4.12 and a debt-to-equity ratio of 0.51. The stock has a market capitalization of $472.81 million, a PE ratio of -7.59 and a beta of 0.79. Treace Medical Concepts, Inc. has a 12-month low of $3.93 and a 12-month high of $10.79. The company has a 50 day moving average price of $7.61 and a two-hundred day moving average price of $7.93.

Treace Medical Concepts (NASDAQ:TMCI) last issued its quarterly earnings data on Thursday, May 8th. The company reported ($0.25) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.31) by $0.06. Treace Medical Concepts had a negative net margin of 30.33% and a negative return on equity of 51.12%. Treace Medical Concepts’s quarterly revenue was up 2.9% on a year-over-year basis. During the same period in the previous year, the firm earned ($0.30) earnings per share. As a group, equities analysts predict that Treace Medical Concepts, Inc. will post -0.92 earnings per share for the current fiscal year.

Treace Medical Concepts Profile

Treace Medical Concepts, Inc, a medical technology company, designs, manufactures, and markets medical devices in the United States. The company offers Lapiplasty 3D bunion correction system that combines instruments, implants, and surgical methods designed to surgically correct three planes of the bunion deformity.